A detailed history of Royal Bank Of Canada transactions in Immunome Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 33,536 shares of IMNM stock, worth $401,761. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,536
Previous 32,754 2.39%
Holding current value
$401,761
Previous $396,000 23.74%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.7 - $16.51 $9,149 - $12,910
782 Added 2.39%
33,536 $490,000
Q2 2024

Aug 14, 2024

BUY
$11.54 - $22.11 $55,795 - $106,901
4,835 Added 17.32%
32,754 $396,000
Q1 2024

Nov 05, 2024

SELL
$11.01 - $27.34 $53,233 - $132,188
-4,835 Reduced 14.76%
27,919 $689,000
Q1 2024

May 15, 2024

SELL
$11.01 - $27.34 $17,230 - $42,787
-1,565 Reduced 5.31%
27,919 $689,000
Q4 2023

Feb 14, 2024

BUY
$7.3 - $10.73 $6,774 - $9,957
928 Added 3.25%
29,484 $315,000
Q3 2023

Nov 14, 2023

SELL
$6.17 - $9.16 $1,486 - $2,207
-241 Reduced 0.84%
28,556 $238,000
Q2 2023

Aug 14, 2023

BUY
$4.7 - $7.91 $4,032 - $6,786
858 Added 3.07%
28,797 $227,000
Q1 2023

May 15, 2023

BUY
$3.26 - $5.69 $202 - $352
62 Added 0.22%
27,939 $139,000
Q4 2022

Feb 14, 2023

SELL
$2.21 - $5.0 $1,365 - $3,090
-618 Reduced 2.17%
27,877 $61,000
Q3 2022

Nov 14, 2022

BUY
$3.39 - $6.14 $393 - $712
116 Added 0.41%
28,495 $126,000
Q2 2022

Aug 15, 2022

SELL
$2.24 - $5.79 $344 - $891
-154 Reduced 0.54%
28,379 $91,000
Q1 2022

May 16, 2022

BUY
$3.88 - $13.99 $1,280 - $4,616
330 Added 1.17%
28,533 $162,000
Q3 2021

Nov 15, 2021

BUY
$12.5 - $27.76 $950 - $2,109
76 Added 0.27%
28,203 $686,000
Q2 2021

Aug 16, 2021

BUY
$16.33 - $32.33 $459,313 - $909,345
28,127 New
28,127 $487,000

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $145M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.